drugset / Trial / NCT02683395

A Study of PLX51107 in Advanced Malignancies

NCT02683395

Phase 1 Terminated 50 enrolled Plexxikon
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the investigational drug PLX51107 in subjects with advanced solid tumors (including lymphoma), and advanced hematological malignancies

Timeline

Start
2016-03
Primary completion
2018-09
Completion
2018-09

Drugs

EvaluationDrugModalityDoseRoute
Subject PLX51107 Small molecule